White label ELPA - ClinicalTrials.eu

Study of CLU-RX-BET injection therapy for patients with moderate to severe birch pollen allergies

Not recruiting

4 1
Title: Long-term safety and effectiveness study of Ulviprubart in patients with inclusion body myositis who completed previous treatment

Not recruiting

3 1 1
Investigated Diseases:
- Inclusion body myositis
Investigated Drugs:
- ULVIPRUBART
Study of TEV-53408 Safety and Effectiveness in Adults with Celiac Disease During Gluten Exposure

Not recruiting

2 1
Investigated Diseases:
- Coeliac disease
Investigated Drugs:
- TEV-53408
Study on the Effect and Safety of BW-20805 for Adults with Hereditary Angioedema

Not recruiting

2 1 1
Investigated Drugs:
- BW-20805
Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Stage I Triple-Negative Breast Cancer

Not recruiting

2 1 1 1
Investigated Diseases:
- Triple negative breast cancer
Investigated Drugs:
Study of pacritinib effectiveness and safety compared to placebo in patients with VEXAS syndrome

Not recruiting

2 1
Investigated Diseases:
- VEXAS syndrome
Investigated Drugs:
- Pacritinib
Study on the Effectiveness and Safety of Finerenone for Patients with Chronic Kidney Disease and Type 1 Diabetes

Not recruiting

3 1
Investigated Drugs:
- Finerenone
Study on the Effectiveness and Safety of Frexalimab and Teriflunomide for Adults with Relapsing Multiple Sclerosis

Not recruiting

3 1 1

+12
Study on the Safety and Effectiveness of CSL889 for Adults and Adolescents with Sickle Cell Disease During Painful Crises

Not recruiting

4 1
Investigated Diseases:
- Sickle cell anaemia with crisis
Investigated Drugs:
- HEMOPEXIN, HUMAN
+1
Study on the Effectiveness and Safety of JNJ-77242113 for Patients with Active Psoriatic Arthritis Who Have Not Used Biologic Treatments

Not recruiting

3 1 1
Investigated Drugs:
- Ustekinumab
- Jnj-77242113
+1

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies